BiOkuris wins the Vitafoods jury’s award of the Most Sustainable Ingredient.
Read moreBiOkuris develops next generation medical nutrition products tailored to the unmet medical needs of patients with chronic intestinal diseases.
We believe that patients deserve specific, safe, effective, and science-driven treatments that reduce their daily burden and help them to restore balance.
Our solutions have been specifically designed to improve both the physiopathology and quality of life for the millions of patients living with chronic intestinal diseases.
Discover our innovative platform40% of Crohn’s disease and ulcerative colitis patients with long-standing remission continue to experience IBS (Irritable Bowel Syndrome)-like symptoms.
Even during and after treatment involving biosimilars and a full control of inflammation, 40% of patients still suffer from abdominal pain, bloating, constipation, or diarrhea.
The etiology of IBS/IBS-like symptoms is multifactorial, combining hypersensitivity of the digestive tract, low-grade local inflammation, and changes in the intestinal flora with dysbiosis, increased intestinal permeability and bile acid malabsorption.
Existing and available drugs are only modestly effective, often developed to improve transit disorders and/or stool consistency via non-irritating laxatives for constipation, transit retarders for diarrhea, antispasmodics for bloating and anxiolytics.
Such ‘IBS-like symptoms’ in IBD patients need to be both comprehensively and specifically targeted to fully satisfy patients’ expectations and radically improve their quality of life.
IBS is a public health problem that affects 10-20% of the population, predominantly affecting women in Europe and North America. With a peak level of frequency between the ages of 20 and 40, it causes young individuals to experience significantly disabling symptoms, resulting in a considerable reduction in their quality of life.
The physiopathology is complex and multifactorial, with existing treatments in Europe only providing a temporary relief of symptoms, without truly addressing the underlying causes. The margin of therapeutical gains when trialed together with placebos rarely exceeds 10%.
BiOkuris is committed to providing targeted, clinically-proven solutions for IBS patients, ensuring a complete and multifactorial effect on their physiopathology, thereby improving their quality of life.
Candida albicans is a type of yeast that can colonize any segment of the digestive tract or vagina. Its deleterious effects are well documented, ranging locally from potentially IBD-caused colitis to cutaneous-mucosal candidiasis, with vaginal candidiasis occurring in 75% of women at least once in their lives, and systemic infections that often occur in hospital, incurring significant medical and financial cost.
As the gut is the source of Candida albicans, targeting this commensal in the gut itself could reduce, even prevent, fungal infections in millions of people each year.
Our technology is based on a model that combines chitin-glucan or chitosan.
Our two proprietary active ingredients are derived from nature, vegan, safe, and non-GMO, both manufactured in Belgium. We have already yielded exceptional results via multiple in vitro, in vivo, and human clinical trials that confirmed its beneficial effects.
Biocopolymer of chitine betaglucan with prebiotic properties
Cationic biopolymer with antifungal and film forming capacities
We are opening a multitude of potential applications in various diseases in combination with other ingredients. This means that our ingredients hold the promise for innovative applications in treating diseases, from chronic conditions affecting the digestive system, such as IBS and IBD, to systemic issues like inflammation and immune system disorders.
The possibility of combining our ingredients with others opens up a new frontier in personalized medicine, where treatments can be tailored to the unique needs and conditions of individual patients.
Experience relief from gas and bloating and restore a healthy gut microbiota with our unique solution BK001
BK001 targets and alleviates gas-related symptoms, including bloating, flatulence, and abdominal pain, offering users a sense of comfort and relief.
It aids in the regularization and normalization of intestinal transit, promoting smoother stool evacuation. Additionally, BK001 contributes to the normalization of intestinal function, supporting overall digestive health.
This product presents a valuable addition to any health and wellness line, providing customers with a solution that addresses common digestive discomforts through its unique properties.
Our company is located near Liege, in Belgium, and we benefit from the rich ecosystem of the “biotech-pharma valley” in Wallonia, allowing us to get access to the best resources to develop our projects. BiOkuris is part of the KitoZyme Group, who for the last 20 years has specialized in the design and manufacturing of biopolymers for Health & Nutrition, Agriculture and Personal Care.
BiOkuris stands at the forefront of gastrointestinal healthcare innovation.
Our nutritional solutions are designed to alleviate the symptoms and improve the lives of those affected by gastrointestinal conditions. Our focus lies in harnessing the power of natural biopolymers, chitin-glucan and chitosan, derived from Aspergillus niger, to create products with innovative synergies that offer real health benefits beyond traditional pharmaceuticals.
As a company, our work encompasses a comprehensive portfolio that extends from pre-clinical developments through to clinical studies, culminating in a commercial product that is establishing its presence in the market.
BiOkuris is led by a team combining expertise in Consumer Health, Pharmaceuticals, Biotechnology and Clinical Medicine.